Takeda to acquire rights to Hutchmed’s cancer drug fruquintinib for $400M upfront

Takeda Pharmaceutical Company

hapabapa/iStock Editorial through Getty Images

Takeda (NYSE:TAK) signed a licensing settlement with Hutchmed (China) (NASDAQ:HCM) to develop and commercialize oral cancer drug fruquintinib exterior of mainland China, Hong Kong and Macau.

Under the settlement, Takeda can pay $400M upfront, up to $730M in

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!